Form 4: Liquidia Corp's Chief Medical Officer Rajeev Saggar Reports Stock Sale to Cover Taxes

Rajeev Saggar, Chief Medical Officer of Liquidia Corp, reports selling 1,649 shares of common stock on April 19, 2024, to cover taxes associated with the settlement of restricted stock units.

Summary

• On April 19, 2024, Rajeev Saggar, the Chief Medical Officer of Liquidia Corp, sold 1,649 shares of common stock.
• The sale was executed at a price of $13.68 per share.
• This transaction was made pursuant to a Rule 10b5-1 plan adopted on December 15, 2023.
• The shares were sold to cover taxes associated with the settlement of restricted stock units (RSUs) granted on July 18, 2022.
• Following the reported transaction, Saggar beneficially owns 211,672 shares of Liquidia Corp.
• This total includes unvested RSUs from grants made on July 18, 2022 (29,323 shares), January 11, 2023 (57,291 shares), and January 11, 2024 (56,492 shares), as well as 3,604 shares acquired under the 2020 Employee Stock Purchase Plan.

Sentiment

Score: 5

Explanation: The document describes a routine transaction (stock sale to cover taxes) by an executive, executed under a pre-arranged plan. It doesn't inherently indicate positive or negative sentiment regarding the company's prospects.

Industry Context

Executive stock sales are a common occurrence, often related to compensation and tax obligations. The use of a 10b5-1 plan suggests the sale was pre-planned and not based on insider information.

Comparison to Industry Standards

• Executive compensation packages often include stock options and restricted stock units (RSUs) as incentives.
• Selling shares to cover tax obligations upon vesting of RSUs is a standard practice among executives in publicly traded companies.
• Rule 10b5-1 plans are frequently used by corporate insiders to schedule stock sales in advance, ensuring compliance with insider trading laws; similar plans are used by executives at companies like Amgen, Biogen, and Gilead Sciences.

Key Dates